Polycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 patients in the United States. Patients can be classified as having low- or high-risk PV, each of which has its own treatment approach and prognosis. Although current pharmacologic treatment is considered adequate for a relatively large group of PV patients, certain population segments are associated with substantial unmet need. As such, there is commercial opportunity for therapies able to differentiate from the current standard of care. Understanding the treatment dynamics is critical to identifying those opportunities.
The report answers key questions including:
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PV patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PV patients?
- How has ruxolitinib (Jakafi) been integrated into the treatment algorithm, and what is its source of business?
- What percentage of PV patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
- What percentage of PV patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
- Polycythemia Vera - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Author(s): Kanika Ujla
Kanika Ujla is an Analyst for the Infectious, Niche, & Rare Diseases (INRD) team at Decision Resources Group. In this role she supports the team by conducting primary and secondary research across a range of antibacterial and antiviral indications as well as numerous niche and rare diseases. She holds experience in R&D, consulting, business research with healthcare and life sciences companies